A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 506 participants.

Also called NCT02420262

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 506 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02420262
  • EudraCT 2014-003621-18
Other papers using this trial's data
  • Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial Diabetes care, 2018-05 DOI, PubMed 29483185
  • The Benefit of Insulin Degludec/Liraglutide (IDegLira) Compared With Basal-Bolus Insulin Therapy is Consistent Across Participant Subgroups With Type 2 Diabetes in the DUAL VII Randomized Trial Journal of diabetes science and technology, 2021-05 DOI, PubMed 32107930, PMC8120051 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Czechia, France, Greece, Hungary, Israel, Mexico, Russia, Slovakia, Spain, Türkiye (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02420262. Randomized; no masking; primary purpose treatment. Start 2015-07-26 (actual); primary completion 2016-10-05 (actual). Results posted on 2017-12-07.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
insulin degludec/liraglutide
Intervention (Drug)
insulin glargine
Intervention (Drug)
insulin aspart
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct02420262
Content hash
6f12307d1ecc02033d2cbe6186b63afd6df1af188209b9230d7ebd124411f7a1